Edition:
United States

Rexahn Pharmaceuticals Inc (RNN.A)

RNN.A on American Stock Exchange

4.04USD
26 May 2017
Change (% chg)

$0.09 (+2.28%)
Prev Close
$3.95
Open
$3.95
Day's High
$4.05
Day's Low
$3.91
Volume
26,923
Avg. Vol
56,180
52-wk High
$7.10
52-wk Low
$1.29

RNN.A

Chart for RNN.A

About

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein... (more)

Overall

Beta: -0.54
Market Cap(Mil.): $102.70
Shares Outstanding(Mil.): 25.42
Dividend: --
Yield (%): --

Financials

  RNN.A Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -1.14 -- --
ROI: -133.38 -8.48 -5.42
ROE: -291.94 -11.31 -4.68

BRIEF-Rexahn Pharmaceuticals files for mixed shelf offering of up to $150 mln‍​

* Rexahn Pharmaceuticals files for mixed shelf offering of up to $150 million - sec filing‍​ Source text (http://bit.ly/2s4PKc4) Further company coverage:

May 26 2017

BRIEF-Rexahn Pharmaceuticals reports Q1 loss per share $0.09

* Rexahn Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

May 04 2017

BRIEF-Rexahn announces 1-for-10 reverse stock split

* Expects that reverse stock split will be effective on May 5, 2017 Source text for Eikon: Further company coverage:

Apr 13 2017

BRIEF-Rexahn Pharma's cash and investments totaled about $20.3 mln as of Dec 31, 2016

* Rexahn Pharmaceuticals reports full year 2016 financial results and provides corporate update

Feb 27 2017

BRIEF-Rexahn Pharmaceuticals announced update on safety, efficacy of RX-3117 in ongoing phase IIa clinical trial in metastatic pancreatic cancer

* Rexahn pharmaceuticals - announced update on safety and efficacy of rx-3117 in an ongoing phase IIa clinical trial in metastatic pancreatic cancer

Jan 20 2017

More From Around the Web

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,643.50 +25.50
Merck & Co., Inc. (MRK.N) $64.92 -0.12

Earnings vs. Estimates